The latest price target for Karyopharm Therapeutics (NASDAQ:KPTI) was reported by Piper Sandler on March 30, 2026. The analyst firm set a price target for $8.00 expecting KPTI to fall to within 12 months (a possible -7.08% downside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Karyopharm Therapeutics (NASDAQ:KPTI) was provided by Piper Sandler, and Karyopharm Therapeutics reiterated their overweight rating.

The last upgrade for Karyopharm Therapeutics Inc happened on October 13, 2025 when HC Wainwright & Co. raised their price target to $15. HC Wainwright & Co. previously had a neutral for Karyopharm Therapeutics Inc.

The last downgrade for Karyopharm Therapeutics Inc happened on July 16, 2025 when HC Wainwright & Co. changed their price target from N/A to N/A for Karyopharm Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karyopharm Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karyopharm Therapeutics was filed on March 30, 2026 so you should expect the next rating to be made available sometime around March 30, 2027.

While ratings are subjective and will change, the latest Karyopharm Therapeutics (KPTI) rating was a reiterated with a price target of $12.00 to $8.00. The current price Karyopharm Therapeutics (KPTI) is trading at is $8.61, which is out of the analyst’s predicted range.